Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00536601 · OUTCOME

Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors)

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors · Source last updated 2021-04-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Proportion of participants
Interval / dispersion
95% Confidence Interval
Time frame
From the date of transplantation to the date of first observed disease progression or death due to any cause, assessed up to 12 years

What was measured

Assessed using the product-limit based Kaplan Meier method. Additionally, a 95% confidence interval of the distribution will be computed.

Analysis population: Each disease strata presents PFS for each conditioning regimen defined in the protocol

Groups in this outcome

Acute Leukemia

Patients diagnosed with and treated for acute myeloid leukemia or acute lymphoblastic leukemia

Hodgkin Lymphoma

Patients diagnosed with and treated for Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Patients diagnosed with and treated for Non-Hodgkin Lymphoma

MM/Amyloid

Patients diagnosed with or treated for multiple myeloma or amyloidosis

Solid Tumors

Patients diagnosed with and treated for a solid tumor

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Acute Leukemia6
Hodgkin Lymphoma21
Non-Hodgkin Lymphoma71
MM/Amyloid65
Solid Tumors11

Reported measurements

BuCy

Analysis denominator · Participants

GroupSource count
Acute Leukemia6
Hodgkin Lymphoma7
Non-Hodgkin Lymphoma27
MM/Amyloid0
Solid Tumors0
Values in Proportion of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Acute Leukemia33Not reported071Not reported
Hodgkin Lymphoma14Not reported040Not reported
Non-Hodgkin Lymphoma22Not reported738Not reported
CBV

Analysis denominator · Participants

GroupSource count
Acute Leukemia0
Hodgkin Lymphoma14
Non-Hodgkin Lymphoma43
MM/Amyloid0
Solid Tumors0
Values in Proportion of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Hodgkin Lymphoma43Not reported1769Not reported
Non-Hodgkin Lymphoma37Not reported2352Not reported
VCp

Analysis denominator · Participants

GroupSource count
Acute Leukemia0
Hodgkin Lymphoma0
Non-Hodgkin Lymphoma1
MM/Amyloid0
Solid Tumors7
Values in Proportion of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Non-Hodgkin Lymphoma0Not reported00Not reported
Solid Tumors43Not reported680Not reported
Mel120

Analysis denominator · Participants

GroupSource count
Acute Leukemia0
Hodgkin Lymphoma0
Non-Hodgkin Lymphoma0
MM/Amyloid18
Solid Tumors0
Values in Proportion of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
MM/Amyloid22Not reported241Not reported
Mel200

Analysis denominator · Participants

GroupSource count
Acute Leukemia0
Hodgkin Lymphoma0
Non-Hodgkin Lymphoma0
MM/Amyloid47
Solid Tumors0
Values in Proportion of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
MM/Amyloid13Not reported322Not reported
CyTtCp

Analysis denominator · Participants

GroupSource count
Acute Leukemia0
Hodgkin Lymphoma0
Non-Hodgkin Lymphoma0
MM/Amyloid0
Solid Tumors2
Values in Proportion of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Solid Tumors0Not reported00Not reported
TtC1500

Analysis denominator · Participants

GroupSource count
Acute Leukemia0
Hodgkin Lymphoma0
Non-Hodgkin Lymphoma0
MM/Amyloid0
Solid Tumors2
Values in Proportion of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Solid Tumors50Not reported0100Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        71
        value
        33
      2. group Id
        OG001
        lower Limit
        0
        upper Limit
        40
        value
        14
      3. group Id
        OG002
        lower Limit
        7
        upper Limit
        38
        value
        22
    denoms
    1. counts
      1. group Id
        OG000
        value
        6
      2. group Id
        OG001
        value
        7
      3. group Id
        OG002
        value
        27
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        0
      units
      Participants
    title
    BuCy
  2. categories
    1. measurements
      1. group Id
        OG001
        lower Limit
        17
        upper Limit
        69
        value
        43
      2. group Id
        OG002
        lower Limit
        23
        upper Limit
        52
        value
        37
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        14
      3. group Id
        OG002
        value
        43
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        0
      units
      Participants
    title
    CBV
  3. categories
    1. measurements
      1. group Id
        OG002
        lower Limit
        0
        upper Limit
        0
        value
        0
      2. group Id
        OG004
        lower Limit
        6
        upper Limit
        80
        value
        43
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        1
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        7
      units
      Participants
    title
    VCp
  4. categories
    1. measurements
      1. group Id
        OG003
        lower Limit
        2
        upper Limit
        41
        value
        22
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        18
      5. group Id
        OG004
        value
        0
      units
      Participants
    title
    Mel120
  5. categories
    1. measurements
      1. group Id
        OG003
        lower Limit
        3
        upper Limit
        22
        value
        13
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        47
      5. group Id
        OG004
        value
        0
      units
      Participants
    title
    Mel200
  6. categories
    1. measurements
      1. group Id
        OG004
        lower Limit
        0
        upper Limit
        0
        value
        0
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        2
      units
      Participants
    title
    CyTtCp
  7. categories
    1. measurements
      1. group Id
        OG004
        lower Limit
        0
        upper Limit
        100
        value
        50
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        2
      units
      Participants
    title
    TtC1500
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    2. group Id
      OG001
      value
      21
    3. group Id
      OG002
      value
      71
    4. group Id
      OG003
      value
      65
    5. group Id
      OG004
      value
      11
    units
    Participants
description
Assessed using the product-limit based Kaplan Meier method. Additionally, a 95% confidence interval of the distribution will be computed.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients diagnosed with and treated for acute myeloid leukemia or acute lymphoblastic leukemia
    id
    OG000
    title
    Acute Leukemia
  2. description
    Patients diagnosed with and treated for Hodgkin Lymphoma
    id
    OG001
    title
    Hodgkin Lymphoma
  3. description
    Patients diagnosed with and treated for Non-Hodgkin Lymphoma
    id
    OG002
    title
    Non-Hodgkin Lymphoma
  4. description
    Patients diagnosed with or treated for multiple myeloma or amyloidosis
    id
    OG003
    title
    MM/Amyloid
  5. description
    Patients diagnosed with and treated for a solid tumor
    id
    OG004
    title
    Solid Tumors
param Type
NUMBER
population Description
Each disease strata presents PFS for each conditioning regimen defined in the protocol
reporting Status
POSTED
time Frame
From the date of transplantation to the date of first observed disease progression or death due to any cause, assessed up to 12 years
title
Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors)
type
PRIMARY
unit Of Measure
Proportion of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice